BioSpace News Archive

Aquarius Surgical Technologies Inc. announces further developments following the announcement on February 22, 2021, that Gordon Willox had been removed as a director and officer of Surgical Lasers Inc., the principal operating subsidiary of ASTI.

The American Medical Association has recognized a CPT code for laser ablation, under imaging guidance, of benign thyroid nodules.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its fourth quarter and full year ended December 31, 2020.

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record Total Revenue and CytoSorb® sales in 2020, and record Product Gross Margins in Q4 202

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 160,800 shares of the Company’s common stock at an exercise price per share of $31.49, which was the closing price on March 8, 2021.

MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein, and peptide technologies, will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT).

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.